SpringerLink
Log in

Influence of Darolutamide on Cabazitaxel Systemic Exposure

  • Research Letter
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat. 2021;56: 100761. https://doi.org/10.1016/j.drup.2021.100761.

    Article  CAS  PubMed  Google Scholar 

  2. Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, et al. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine. 2021;5(73): 103681. https://doi.org/10.1016/j.ebiom.2021.103681.

    Article  CAS  Google Scholar 

  3. Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, et al. Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients. Clin Cancer Res. 2018;24(3):541–6. https://doi.org/10.1158/1078-0432.CCR-17-2336.

    Article  CAS  PubMed  Google Scholar 

  4. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–9. https://doi.org/10.1056/NEJMoa2001342.

    Article  CAS  PubMed  Google Scholar 

  5. Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747–59. https://doi.org/10.1007/s13318-019-00577-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, et al. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. J Pharm Biomed Anal. 2012;5(59):11–22. https://doi.org/10.1016/j.jpba.2011.10.010.

    Article  CAS  Google Scholar 

  7. Eisenberger M, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer: PROSELICA. J Clin Oncol. 2017;35(28):3198–206. https://doi.org/10.1200/JCO.2016.72.1076.

    Article  CAS  PubMed  Google Scholar 

  8. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31. https://doi.org/10.1056/NEJMoa1903835.

    Article  CAS  PubMed  Google Scholar 

  9. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695–707. https://doi.org/10.1016/S0140-6736(22)00367-1.

    Article  CAS  PubMed  Google Scholar 

  10. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2119115.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowlegdements

The authors would like to thank Stichting DUOS for their support.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Dr Molewaterplein 40, 3015GD, Rotterdam, The Netherlands

    Stefan A. J. Buck, Niels A. D. Guchelaar, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Esther Oomen-de Hoop, Martijn P. Lolkema, Stijn L. W. Koolen, Ronald de Wit & Ron H. J. Mathijssen

  2. Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands

    Hans M. Westgeest

  3. Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam/Schiedam, The Netherlands

    Paul Hamberg & Danielle Mathijssen-van Stein

  4. Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

    Stijn L. W. Koolen

Authors
  1. Stefan A. J. Buck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niels A. D. Guchelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter de Bruijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Inge M. Ghobadi Moghaddam-Helmantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Esther Oomen-de Hoop
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans M. Westgeest
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul Hamberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Danielle Mathijssen-van Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martijn P. Lolkema
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stijn L. W. Koolen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ronald de Wit
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ron H. J. Mathijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan A. J. Buck.

Ethics declarations

Funding

Bayer provided funding for the preparation of this article. 

Conflicts of Interest/Competing Interests

HW: honoraria; Astellas and Roche and travel expenses; Astellas and Ipsen. PH: consulting fees; Astellas, MSD, Pfizer, AstraZeneca, BMS and Ipsen. MPL: advisory role/speaker fees; Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer Sanofi Aventis Netherlands BV and Astellas and has received research funding (institutional) from Sanofi, JnJ, Merck and Astellas. RDW: advisory role/speaker fees; Sanofi, Merck, Lilly, Roche, Bayer, Janssen Cilag B.V. and Clovis and research funding (institutional); Sanofi and Bayer. RHJM: has received research funding (institutional) from Bayer, Sanofi and Astellas.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Authors’ Contributions

Conceptualisation: SB, RdW, RM; methodology: SB, RM, SK, PdB; formal analysis: SB, EOdH; investigation: SB, NG; resources: PdB, SB; data curation: SB, NG, writing, original draft: SB; writing, review and editing: all authors.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 19 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buck, S.A.J., Guchelaar, N.A.D., de Bruijn, P. et al. Influence of Darolutamide on Cabazitaxel Systemic Exposure. Clin Pharmacokinet 61, 1471–1473 (2022). https://doi.org/10.1007/s40262-022-01159-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-022-01159-6

Search

Navigation